Tony Berberabe | Authors


Early Responses Observed With Lu-PSMA Administration May Provide Prognostic Outlook in mCRPC

August 13, 2020

Prostate-specific antigen changes were observed 6 weeks after the administration of 177Lu-PSMA in men with metastatic castration-resistant prostate cancer, suggesting a prognostic value for long-term clinical benefit, according to a single center retrospective analysis.

Anti-HER2 Agents Explored Further in Gastric, Colorectal, and NSCLC Settings

July 07, 2020

At the recent 2020 American Society of Clinical Oncology Virtual Scientific Program, key research evaluating the use of anti-HER2 agents were highlighted across multiple solid tumors, including gastric or gastroesophageal junction adenocarcinoma, colorectal cancer, and non–small cell lung cancer.